Conyers provided Cayman Islands legal advice to Sino Biopharmaceutical Limited in connection with the issue of an amount not exceeding RMB 1.5 billion medium term notes with maturity not exceeding three years on the National Association of Financial Market Institutional Investors (2024 1st tranche).

Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China. It belongs to the Charoen Pokphand Group and is headquartered in Hong Kong and Beijing. Its business includes researching, developing, producing, and selling biopharmaceutical products. It was listed on the Hong Kong Stock Exchange in 2000 (Stock code: 1177).

Senior Associate Beverly Cheung of Conyers’ Hong Kong office advised on the matter working alongside King & Wood Mallesons (Beijing).

Stay current with our latest legal insights and subscribe today